ALN-APOC3
/ Regeneron, Alnylam
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 03, 2025
ALN-APOC3 in Adult Participants With Dyslipidemia
(clinicaltrials.gov)
- P1/2 | N=136 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Dyslipidemia • Metabolic Disorders
1 to 1
Of
1
Go to page
1